NPS Executes On Ultra-Orphan Gattex Launch With FDA Approval In Hand

Now that NPS Pharmaceuticals Inc.’s first drug, the short bowel syndrome treatment Gattex (teduglutide), has been approved by FDA, the company is focused on making the product a commercial success in the ultra-orphan drug market. Gattex was approved by FDA Dec. 21, one week ahead of the PDUFA date, marking NPS’ long awaited transition from R&D boutique to commercial biopharma.

During a conference call Jan. 2 outlining the commercial launch strategy, management said it would price Gattex at $295,000 per year for treatment, significantly higher than what many analysts and...